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Based on phage display optimization studies with hu-
man growth hormone (GH), it is thought that the biopo-
tency of GH cannot be increased. This is proposed to be
a result of the affinity of the first receptor for hormone
far exceeding that which is required to trap the hor-
mone long enough to allow diffusion of the second re-
ceptor to form the ternary complex, which initiates sig-
naling. We report here that despite similar site 1
kinetics to the hGH/hGH receptor interaction, the po-
tency of porcine GH for its receptor can be increased up
to 5-fold by substituting hGH residues involved in site 1
binding into pGH. Based on extensive mutations and
BIAcore studies, we show that the higher potency and
site 1 affinity of hGH for the pGHR is primarily a result
of a decreased off-rate associated with residues in the
extended loop between helices 1 and 2 that interact with
the two key tryptophans Trp104 and Trp169 in the recep-
tor binding hot spot. Our mutagenic analysis has also
identified a second determinant (Lys165), which in addi-
tion to His169, restricts the ability of non-primate hor-
mones to activate hGH receptor. The increased biopo-
tency of GH that we observe can be explained by amodel
for GH receptor activation where subunit alignment is
critical for effective signaling.
The growth hormone receptor (GHR)1 was the first class 1
cytokine receptor to be characterized, and the interaction be-
tween the human receptor and its ligand has been particularly
well characterized (1, 2). The GHR has served as a paradigm for
the ligand-induced dimerization mechanism that is believed to
result in the activation of paired Janus kinases bound to the
membrane proximal box 1 sequence of the receptor by a process
of transphosphorylation. In the case of the GHR, JAK2 is the
proximal effector, and once activated, it phosphorylates selected
tyrosines in the receptor cytoplasmic domain, providing docking
sites for SH2-domain containing signaling proteins and adaptors.
Several important pathways are activated by this process, in-
cluding the STAT5a/b, the ERK, and Akt pathways (3).
In a series of elegant investigations, a Genentech group
demonstrated that the 4-helix bundle hormone possesses two
non-identical binding surfaces, but binds to similar receptor
binding sites in an ordered sequence, with the initial binding
site possessing a higher affinity (site 1). Site 2 binding is
stabilized by a further inter-receptor interaction involving the
“dimerization domain” in the lower of the two cytokine homol-
ogy modules (4–6). Both site 1 and site 2 interactions are
critically dependent on a key tryptophan contributed by the
upper cytokine module (Trp104), with a second precisely ori-
ented tryptophan (Trp169) from the lower module also contrib-
uting critically to site 1 binding (2, 7). These tryptophans form
the center of a hydrophobic binding surface (hot spot), which is
the basis for the hormone-receptor interaction, with surround-
ing residues packing around these tryptophans to ensure high
affinity interactions with the relevant hormone residues. System-
atic mutagenesis has shown that essentially, the minihelix and
loop between helices 1 and 2, together with residues in the center
of helix 4 comprise the first hormone binding site 1 (1, 2). Resi-
dues at the amino terminus of the first helix and helix 3 comprise
the second and smaller binding site on the hormone (5, 6).
Simulation of the process of bivalent hormone-dependent
dimerization of receptor subunits shows that increasing site 1
affinity will shift the dose-response curve leftwards, whereas
increasing site 2 affinity increases the maximum response (8,
9). The Genentech group therefore sought to increase the po-
tency of human GH by increasing the affinity of both site 1 and
site 2 for the receptor using phage display. However, despite a
400-fold increase in site 1 affinity, or a 40-fold increase in site
2 affinity, no increase in potency of hGH was observed in a cell
proliferation assay (10). This led these workers to conclude that
hGH is evolutionarily “optimized,” because site 1 affinity in
particular was sufficient to trap the hormone at the cell surface
long enough for efficient dimerization with the second receptor
subunit following its diffusion in the plane of the membrane to
the receptor 1-hormone complex. This optimization is evidently
very effective, because it was necessary to lower site 1 affinity
by around 100-fold to observe a significant increase in the EC50
for cell proliferation (10).
While developing a cell proliferation assay for porcine GH
based on stable expression of the pGH receptor, we noted that
the biopotency of human GH was 5-fold greater than that of
pGH. In an effort to understand the mechanisms responsible
for this difference, and to create higher potency pGH analogues
with economic potential, we have substituted site 1 binding
residues from hGH residues into pGH. This also allowed us to
identify species-specific determinants for hGH binding. We find
that, contrary to hGH, it is possible to improve the biopotency
of pGH, both by increasing on-rate and by decreasing off-rate
constants. Our observations are consistent with a model for GH
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receptor activation that involves a hormone-induced conforma-
tional change within a constitutive dimer, rather than hor-
mone-induced receptor dimerization. Such a model has been
proposed recently based on FRET and BRET data, and the
ability to create constitutively active receptors independent of
hormone by relative rotation of receptor subunits.2
EXPERIMENTAL PROCEDURES
Hormones
Recombinant hGH was obtained from the National Institute for
Biological Standards and Control, Herts, UK, and interleukin-3 was a
generous gift of Andrew Hapel, Australian National University, Can-
berra, Australia.
Mutagenesis
Gene Splicing by Overlap Extension mutagenesis (12) was employed
to construct four cluster mutants based on the sequence comparison
shown in Fig. 1, where residues in site 1 of hGH and the equivalent
residues in pGH are highlighted. The primers listed below were used for
the mutagenesis of the target residues R41K/Insert44F/I45L in group 1
(G1), T62S/G63N/K64R/D65E/A67T in group 2 (G2), K165R/L168M/H-
169D/A172V in group 3 (G3), and V178I/M179V/K180Q/del.183R/F184S
in group 4 (G4). Each mutation is indicated in bold type, and the overlap
regions are underlined. The primers are: PGH-a-For: 5-GGATAACA-
ATTTCACACAGGAGG-3; G1–1b-Rev: 5-TGCAGGAAGGAGTACTT-
CTGTCCCTCCGGGATG-3; G1–1c-For: 5-CAGAAGTACTCCTTCC-
TGCAGAACGCCCAGGCTG-3; G2–1b-Rev: 5-GTCTCTTCCAGGTT-
GCTGGGGGTCGGGATGGTCTC-3; G2–1c-For: 5-CAGCAACAGGG-
AAGAGACCCAGCAGAGATCGGACG-3; G3–1b-Rev: 5-TGTCTCAA-
CCTTGTCCATGTCCTTCCTGAAGCAGG-3; G3–1c-For: 5-TGGAC-
AAGGTTGAGACATTCCTGCGGGTCATGAAG-3; G4–3b-Rev: 5-
CT—GCGACACTGCACGATCCGCAGGTATGTCTCAGC-3; G4–3c-
For: 5-GATCGTGCAGTGTCGC—AGCGTGGAGAGCAGCTGTG-3;
and PGH-d-Rev: 5-CCGCCAAAACAGCCAAGCTTGC-3. Two sepa-
rate fragments containing mutated bases were amplified from the pGH-
pEC611 template by PCR using high fidelity thermostable polymerase,
Pfu (Stratagene, La Jolla, CA). The first fragment was amplified with
primers a and b. Primer b introduces a sequence change at the 3 end of
the PCR product. The second fragment was amplified with primers c
and d, with primer c introducing the same mutation, but in the 5 end
of the PCR product. These two products share a segment of identical
sequence, the overlap region. When these intermediate products are
mixed, melted, and re-annealed, the two complementary mutant se-
quences generated from separate PCR anneal, facilitating overlap
extension by DNA polymerase. This allows the creation of full-length
pGH mutant DNA during the subsequent PCR with primers a and d.
Site-directed mutagenesis was carried out as described by
QuikChange (Stratagene) to create a series of individual pGH mutants
within the four groups described above. The following primers were
used, where mutated bases are bolded and underlined. The primers are:
G1–3For (R42K): 5-TCCCGGAGGGACAGAAGTACTCCATCCAGAA-
CG-3; G1–3Rev (R42K): 5-CGTTCTGGATGGAGTACTTCTGTCCCT-
CCGGGA-3G1–4For (45F/I46L): 5-GACAGAGGTACTCCTTCCTGC-
AGAACGCCCAGGCTG-3; G1–4For (45F/I46L): 5-CAGCCTGGGCG-
TTCTGCAGGAAGGAGTACCTCTGTC-3; G2–2For (T62S/G63N): 5-
CCATCCCGGCCCCCAGCAACAAGGACGAGGCCCAG-3; G2–2Rev
(T62S/G63N): 5-CTGGGCCTCGTCCTTGTTGCTGGGGGCCGGGAT-
GG-3; G2–4For (K64R/D65E): 5-GCCCCCACGGGCAGGGAAGAGG-
CCCAGCAGAGATC-3; G2–4Rev (K64R/D65E): 5-GATCTCTGCTGG-
GCCTCTTCCCTGCCCGTGGGGGC-3; G2–5For (A67T): 5-ACGGGC-
AAGGACGAGACCCAGCAGAGATCGG-3; G2–5Rev (A67T): 5-CCG-
ATCTCTGCTGGGTCTCGTCCTTGCCCGT-3; G3–1For (K165R): 5-
CTGCTCTCCTGCTTCAGGAAGGACCTGCACAAG-3; G3–1Rev
(K165R): 5-CTTGTGCAGGTCCTTCCTGAAGCAGGAGAGCAG-3;
G4–1For (V177I): 5-GAGACATACCTGCGGATCATGAAGTGTCGCC-
G-3; G4–1Rev (V177I): 5-CGGCGACACTTCATGATCCGCAGGTAT-
GTCTC-3; G4–2For (V177I/M178V/K179Q): 5-GACATACCTGCGGA-
TCGTGCAGTGTCGCCGCTTCG-3; G4–2Rev (V177I/M178VK179/Q):
5-CGAAGCGGCGACACTGCACGATCCGCAGGTATGTC-3; G4–
6For (F184S): 5-CATGAAGTGTCGCCGCAGCGTGGAGAGCA-
GCTGTG-3; G4–6Rev (F184S): 5-CACAGCTGCTCTCCACGCTGCG-
GCGACACTTCATG-3; G4–7For (del.R183/F184S): 5-CATGAAGT-
GTCGC—AGCGTGGAGAGCAGCTGTG-3; G4 –7Rev (del.R183/
F184S): 5-CACAGCTGCTCTCCACGCT—GCGACACTTCATG-3.
GHBP Mutations
To facilitate bacterial expression of pGHBP, a number of third bases
in the wild type pGHBP DNA were mutated to the preferred bacterial
codons, where the mammalian codon was only rarely used in Escheri-
chia coli. There were codons 21 (GGG to GGT), 25 (ACA to ACC), 28
(GTC to GTG), 29 (CTT to CTG), 30 (GTC to GTG), 31 (AGA to CGT), 38
(AGA to CGT), and 174 (AGA to CGT). In addition, to facilitate coupling
to the BIAcore chip, pGHBP(S201C), pGHBP(S237C), and hGHBP(S-
201C) were prepared by site-directed mutagenesis from pGHBP and
hGHBP cDNAs in pCDNA3.1() with the following primers. The
mutated bases corresponding to amino acid substitutions are bolded
and underlined. The primers are: S219C-pGHBP-For: 5-CAGTTCCG-
GTGTACTGCTTGAGACTG GATAAAG-3; S219C-pGHBP-Rev: 5-CT-
TTATCCAGTCTCAAGCAGTACACCGGAACTG-3; S237C-pGHBP-F-
or: 5-CACTTCCTCAGATGTGCTAATAAGCTTGTGAAGAAG-3;
S237C-pGHBP-Rev:5-CTTCTTCACAAGCTTATTAGCACATCTGAG-
GAAGTG3; S219C-hGHBP-For: 5-CATCAGTTCCAGTGTACTGCTT-
GAAAGTGGATAAG-3; S219C-hGHBP-Rev: 5-CTTATCCACTT-
TCAAGCAGTACACTGGAACTGATG-3.
Expression Constructs
Expression in E. coli also required the removal of the mammalian
signal sequence. This was achieved by introducing an NdeI site and a
START codon (ATG) at the 5 end and a STOP codon (TAA) and a
HindIII site at the 3 end of the pGH, pGHBP, and hGHBP sequences
in pCE611(pGH), pCDNA3.1(pGHBP), and pCDNA3.1(hGHBP). The
following primers were used to achieve this by site-directed
mutagenesis. The restriction sites are bolded and underlined, and start
and stop codons are in italics: pGH-For: 5-GAAACAGCATATGTTCC-
CAGCCATGCCGC-3; pGH-Rev: 5-CAGCCAAGCTTCTATGCCTGC-
AGGTCGACTC-3; PGHBP-For: 5-CAGGCTCACATATGGCTTTTTC-
TGGGAGTGAAGCC-3; pGHBP-Rev: 5-TTCACAAGCTTATTAGCTC-
ATCTGAGGAAGTGTTAC-3; hGHBP-For: 5-CAGGCTCACATATGT-
TTTCTGGAAGTGAGGCC-3; hGHBP-Rev: 5-TTCACAAGCTT-
ATTAGCTCATCTGAGGAAGTGTTAC-3.
After each mutation was confirmed by autosequencing using the
ABI Prism big dye terminator version 3.0 (Australian Genome Re-
search Facility), the mutant cDNAs were digested with the relevant
restriction enzymes such that the mutated region was excised. The
pET-20b() expression vector (catalog number 69739-3, Novagen,
Madison, WI) was also cut with the same enzymes followed by liga-
tion of the mutant DNA segment. The mutant cDNA segments in the
expression vector were again sequenced between the subcloning sites
to eliminate any spurious mutations.
Expression and Purification of Recombinant Proteins
pGH and pGHMutants—All constructs were transformed into E. coli
strain BL21(DE3), and isolated colonies from agar plates were grown in
2 R. J. Brown, J. J. Adams, R. A. Pelakanos, Y. Wan, W. J. McKinstry,
K. Palethorpe, R. M. Seeber, T. A. Monks, K. A. Eidne, M. W. Parker,
and M. J. Waters, unpublished data.
FIG. 1. Comparison of human GH site 1 binding residues with
equivalent porcine GH residues. The site 1 binding residues were
divided into four groups (highlighted): group 1, R41K/Insert44F/I45L;
group 2, T61S/G62N/K63R/D64E/A66T; group 3, K165R/L168M/
H169D/A171V; and group 4, V177I/M178V/K179Q/del R182/F183S.
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3-ml cultures, then induced with 1 mM isopropyl-1-thio--D-galactopy-
ranoside. The clones expressing the highest level of recombinant pro-
teins were selected by PAGE using Coomassie Blue and used immedi-
ately for protein expression.
Selected bacterial clones expressing pGH and pGH mutants were
used to initiate fermentation by inoculation in 50 ml of LB medium at
37 °C, followed by an overnight culture at 15 °C. This culture was then
diluted into 500 ml of TB medium and grown in 2  2-liter flasks at
37 °C to an A600 of 0.7–0.9. Isopropyl-1-thio--D-galactopyranoside was
then added to 1 mM. Growth was continued for an additional 3–4 h to
A600 of 1.5–1.6, after which the cells were pelleted for 10 min at 6,000 
g, re-suspended in 20 ml of cold water containing 0.2 mM phenylmeth-
ylsulfonyl fluoride, and stored at 70 °C for less than 2 weeks. For
preparation of inclusion bodies, frozen precipitate was thawed and the
cells were lysed by passage twice through a French Press at 1000 p.s.i.
The lysate was washed by centrifuging sequentially with 100 ml of cold
water, 100 ml of washing buffer 1 (1 M NaCl, 25 mM Na3BO3, pH 9.0),
and 100 ml of washing buffer 2 (phosphate-buffered saline containing 1
M urea and 1% Triton X-100, pH 7.8). In each case the pellets were
resuspended by gentle homogenization with a Polytron, and the sus-
pension was centrifuged at 10,000  g for 12 min at 4 °C. SDS-PAGE
(not shown) revealed that the molecular weight of the recombinant
protein was identical to pGH wild type.
The inclusion body pellets were then re-suspended in 10 ml of dena-
turation buffer (10 mM glycine, 10 mM dithiothreitol, 40 mM sodium
borate, pH 9.1), 4 volumes of 6 M guanidine HCl was added, and the
ixture was stirred for 1 h. After this, the suspension was centrifuged
and the supernatant was diluted with 5 volumes of 4 M urea, 1 mM
glycine, 25 mM Na3BO3 (pH 9.1), such that the refolding was initiated,
and this was facilitated by agitating gently to allow air oxidation, for 5 h
at 4 °C. Oxidation was followed by dialysis against 8 liters of 1 M urea,
25 mM Na3BO3 (pH 9.1) and 2 8 liters of 25 mM Na3BO3 (pH 9.1) for
36 h at 4 °C.
The refolded oxidized protein was then loaded onto a Q-Sepharose
(catalog number 17051010, Amersham Biosciences) column (1.6  20
cm) pre-equilibrated with 25 mM Na3BO3 (pH 9.1) at 4 °C. Elution
was carried out with a continuous NaCl gradient (0–1 M) in the
equilibration buffer at 2 ml/min, and 5-ml fractions were collected.
Protein concentration was determined by absorbance at 280 nm, and
monomer content was determined by 14% SDS-PAGE in the absence
of reducing agents. Gels were stained with Coomassie Blue R-250.
Fractions judged to be greater than 95% pure monomer were selected
for further analysis.
pGHBP and hGHBP—Recombinant porcine GHBP WT,
pGHBP(S201C), and pGHBP(S237C) were expressed in E. coli
BL21(DE3) and purified as described in Wan et al. (13). Wild type
hGHBP and hGHB(S201C) cDNA coding sequence for residues 1–237
was ligated into the pET20b() vector and transformed into E. coli,
BL21 CodonPlus(DE3)-RIL (catalog number 230245, Stratagene) ac-
cording to the instruction manual (revision 050004). Subsequent ex-
pression and purification of these proteins was as described in Wan
et al. (13). Radioligand binding of purified GHBPs was according to
Ref. 14.
Surface Plasmon Resonance
All kinetic experiments were carried out on a BIAcore 3000 instru-
ment (BIAcore AB, Uppsala, Sweden) at 25 °C. pGHbp and hGHbp were
immobilized on Sensor Chips SA (BR-1000–32, BIAcore AB) and
changes in refractive index upon binding of hormone were used for
kinetic measurements.
Preparation of Sensor Chips—To immobilize pGHBP and hGHBP in
discrete orientations on the BIAcore sensor chip SA (streptavidin), a
cysteine residue was introduced at Ser201 or Ser237 as previously de-
scribed (1). In our hands, direct coupling of the free thiol to the sensor
chip inactivated the binding protein. Therefore the free thiols were
conjugated with Biotin-BMCC (Pierce) to form a mixed disulfide, with
excess Biotin-BMCC being removed with a PD-10 desalting column
(Amersham Biosciences). After preconditioning sensor chips with three
consecutive 1-min injections of 1 M NaCl in 50 mM NaOH, biotinylated
GHBPs were immobilized onto the streptavidin at the chip surface until
140 RUs (refractive index unit) were immobilized. This was achieved
by injecting biotinylated GHBPs (2  5 l of 1 g/1 ml in 10 mM sodium
acetate, pH 6.0, buffer) over the chip surface following the BIAcore
protocol. The pGHBP(S201C) and pGHBP(S237C) were immobilized on
the surfaces of flow cells 2 and 4, respectively, and flow cells 1 and 3
were used as reference for on-line reference subtraction. After immobi-
lization, maximum binding capacity was determined by saturating the
biosensor with 240 nM pGH or hGH.
Analyses of Binding Kinetics—Association rates were calculated from
binding profiles obtained by injecting increasing concentrations of each
GH analogue. In all cases, 25 l of 0.5, 3.75, 7.5, 15, 30, and 60 nM
FIG. 2.Representative curves show-
ing proliferative response of BaF/B03
cells expressing pGH receptor to
hGH, pGH wild type (A), and pGH an-
alogues with higher potency (B–D).
Cell proliferation was assessed using the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide assay (see “Experi-
mental Procedures”). The points on the
curves represent normalized absorbance
values (mean  S.E.) from the data of
duplicate experiments with each trial
consisting of triplicate runs. P.Mut.G1-1
represents mutant 1 of porcine GH group
1, and the others are similarly indicated.
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analogue were injected. Each concentration of the analyte was run
three times over the surface of the GHBP Chip at a flow rate of 5 l/min.
Injection time was 5 min, stabilization time was 1 min, and dissociation
time was 5 min. High salt buffer-EP was used to prevent long-range
electrostatic effects and to mimic physiological ionic strength, and non-
specific binding was reduced by including 0.02% Tween 20. The surface
was regenerated by washed for 30 s with 25 l of 4.5 M MgCl2. Control
experiments showed that this was sufficient to remove all the bound
hormone and that the surface could be reused more than 100 times
without significant change in the binding kinetics.
Association and dissociation kinetic constants were calculated by
BIAevaluation 3.2 software using a simple 1:1 Langmuir model. A wild
type reference was always included to control for any chip variation.
The concentration of the hGH, pGH, and analogues were determined by
absorbance at 280 nm and BCA analysis.
Cell Proliferation Assays
The interleukin-3-dependent cell line, BAF/B03, stably transfected
with full-length pGHR or human GH receptor (hGHR) was used for cell
proliferation assays (15). Both lines express around 6000 receptors/cell
at the cell surface by Scatchard analysis. Cells were maintained in
RPMI 1640 media with 10% Serum Supreme (a fetal bovine serum alter-
native supplied by BioWhittaker) and 5 mM hGH. In preparation for the
assay, 80% confluent BAF/B03 cells were washed with phosphate-buff-
ered saline, re-suspended in assay buffer (RPMI 1640 with 1% serum
supreme, without hGH), and incubated for 12–14 h. Cells were then
pelleted, washed with phosphate-buffered saline, and re-suspended to 6
105 cells/ml in assay buffer. 50 l of cell suspension was added to each well
of a 96-well microtiter plate. This was followed by 100 l of pGH or pGH
mutants (at 8 different concentrations: 100, 25, 10, 5, 2.5, 0.625, and 0.1
ng/ml) to each of triplicate wells. Cells were then incubated for 36–40 h at
37 °C, after which 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide was used to determine cell viability and number as described
previously (15). Curve fitting was performed using Prism 3 and derived
EC50 values were compared by analysis of variance. Each mutant was
assayed three times, and the mean values are reported.
Homology Modeling
Protein Data Bank structures 1HWG, 3HHR, and 1A22 were used
as templates for constructing a model of pGH/pGHBP, with pGH and
pGHBP protein sequences being obtained from NCBI. Sequences
were read into InsightII (Accelrys, San Diego, CA) and aligned using
structurally conserved regions within the homology module. For pGH
and pGHBP, 10 structures were built using the modeler function with
a high level of refinement. The structures were minimized using
Discover3 and the CFF91 forcefield. Model structures were scored
with a combination of ProCheck, ProStat, and Verify, and also as-
sessed visually. Models of the highest affinity mutants were also
created using the Biopolymer module. The pGH-pGHBP complex
model was created using 3HHR as a template. pGH and pGHBP were
superimposed onto 3HHR to check for bumps. These were removed by
manual rotation of torsions. The complex was then minimized, and
analyzed by ProCheck and compared with 3HHR. This process was
then performed for mutant structures.
FIG. 3. Proliferative response of
BaF/B03 cells expressing hGH recep-
tor (panels A–C) and pGH receptor
(panel D) to hGH, pGH, and pGH an-
alogues. pGH G3-1 consists of L168M/
H169D/A171V and G3-2 comprises
K165R/L168M/H169D/A171V. Cell prolif-
eration was assessed using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide assay (see “Experimental
Procedures”). The points on the curves
represent absorbance values (mean 
S.E.).
TABLE I
Biopotency values for pGH mutants and hGH relative to pGH
The values shown in this table are means  S.E.
Ligands Mutated residues EC50 relative toPGH wild type
PGH WT 1.00
HGH WT 0.19  0.02a
G1 (1) R41K/Ins.44F/I45L 0.31  0.01a
G1 (3) R41K 0.87  0.02
G1 (4) Ins.44F/I45L 0.50  0.03b
G2 (1) T61S/G62N/K63R/D64E/A66T 0.36  0.03b
G2 (2) T61S/G62N 1.17  0.06
G2 (4) K63R/D64E 1.94  0.06b
G2 (5) A66T 0.65  0.08
G4 (2) V177I/M178V/K179Q 1.15  0.00
G4 (3) V177I/M178V/K179Q/del.182R/F183S 0.60  0.03
G4 (6) F183S 0.46  0.01b
G4 (7) Del.182R/F183S 0.35  0.03b
G5 (1) G1(1)  G2(2) 0.38  0.01b
G5 (2) G1(1)  G2(4) 0.85  0.07
G5 (3) G1(1)  G4(7) 0.22  0.01a
G5 (4) G2(1)  G4(7) 0.26  0.03a
G5 (5) G2(1)  G1(4) 0.24  0.01a
G5 (6) G1(1)  G4(7)  G2(5) 0.22  0.01a
G5 (7) G2(1)  G4(7)  G1(4) 0.20  0.01a
a p  0.01 relative to pGH.
b p  0.05 relative to pGH.
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Molecular Dynamics
Molecular dynamic simulations were performed in the Discover3
module of InsightII. Minimized pGH and pGH-Group 1 were equili-
brated at 300 K, before generating 50 structures using 2000 fs of
molecular dynamic. The structures were analyzed in the DeCipher
module of InsightII, to assess the mobility of the minihelix. Mobility
was measured as the distance between 3 residues located on the same
side of the helix.
RESULTS
Biopotency of Analogues in a pGH Receptor-based Assay—
The 5-fold biopotency difference that prompted this study is
shown in Fig. 2A, which compares the potencies of hGH and
pGH against the pGH receptor in the BaF cell assay. To ad-
dress the basis for this difference, we expressed and purified 20
pGH analogues each possessing different combinations of the
key binding elements of hGH identified for site 1 binding to
receptor 1 (1). This resulted in 4 groups of mutants, correspond-
ing to the minihelix between helices 1 and 2 (G1), R41K/In-
serted 44F/I45L; the extended loop between helices 1 and 2
(G2), T61S/G62N/K63R/D64E/A66T; the central part of helix 4
(G3), K165R/L168M/H169D/A171V; and the carboxyl-terminal
end of helix 4 (G4), V177I/M178V/K179Q/del.182R/F183S (Fig.
1). Variants with individual mutations in each group were also
created. The biopotency curves for several of these are shown in
Fig. 2, B–D, and the EC50 values are listed in Table I.
Of the four groups of pGH analogues, the most significant
reduction in EC50 for cell proliferation were for group 1 (1),
R41K/Inserted 44F/I45L; group 2 (1), T61S/G62N/K63R/D64E/
A66T; and group 4 (7), del.182R/F183S. There were no biopo-
tency-improved variants in group 3. Interestingly, although
neither double nor single mutations showed any significant
reduction in the EC50 in group 2, the sum of all mutations in
TABLE II
Proliferative ability of pGH mutants relative to hGH and pGH wild type
The values shown in this table represent mean  S.E.
Receptor Ligands Mutated residues EC50 relative to pGH wild type
hGHR PGH NR
HGH 1.00
G3(1) L168M/H169D/A171V 19.4  1.26a
G3(2) K165R/L168M/H169D/A171V 5.38  0.15a
G2(1) T61S/G62N/K63R/D64E/A66T NRc
G2(5) A66T NR
pGHR PGH WT 1.00
G3(1) L168M/H169D/A171V 3.05  0.20b
G3(2) K165R/L168M/H169D/A171V 2.28  0.21b
a p  0.01 relative to GH wild type.
b p  0.05 relative to GH wild type.
c NR, no response.
TABLE III
Kinetic data for binding of WT growth hormones to GHBPs immobilized on BIAcore sensor chip SA
1000 RU  1.0 ng/mm2. Stoichiometry of binding were calculated according to the following formula: (RUMax(GH))/(RU (GHBP))  (Mr.
GHBP)/(Mr.GH).
Hormone Matrix Stoichiometry (pGH:pGHBP) Kon Koff KD
s1 M1 nM
pGH WT pGHBP (S201C) 0.89:1 3.4 E  5 6.1 E4 1.80
pGH WT pGHBP (S237C) 0.47:1 5.1 E  5 1.6 E4 0.30
hGH WT hGHBP (S201C) 0.87:1 3.2 E  5 3.9 E4 1.22
TABLE IV
Relative on-rates, off-rates, and affinities for pGH mutants and hGH to pGHbp(S201C) immobilized on the SA-matrix of BIAcore biosensor
The relative change in on-rate was calculated from Kon Mut/Kon WT and off-rate from Koff Mut/KoffWT. The change in KD was calculated as
[Koff /Kon (Mut)]/[Koff /Kon (WT)] and KA from 1/KD. The values of Rmax were calculated from Rmax Mut/Rmax WT. The 		G values were calculated
as RT Ln KD.
Ligands Residues by mutagenesis
Changes in kinetics (Mut/WT)
On-rate Off-rate KA KD Rmax 		G
Kcal/mol
PGH 1.00 1.00 1.00 1.00 1.00 0.00
HGH 0.73 0.08 9.34 0.11 1.17 1.32
G1(1) R41K/Ins.44F/I45L 1.57 0.79 1.98 0.52 1.22 0.39
G1(3) R41K 1.13 1.05 1.03 0.94 1.10 0.04
G1(4) Ins.44F/I45L 1.22 0.63 1.94 0.51 1.29 0.40
G2(1) T61S/G62N/K63R/D64E/A66T 1.17 0.05 23.8 0.04 1.24 1.87
G2(2) T61S/G62N 0.77 0.98 0.80 1.16 1.06 0.09
G2(4) K63R/D64E 0.89 1.92 0.49 2.13 0.69 0.45
G2(5) A66T 0.77 0.42 1.85 0.53 1.14 0.37
G4(3) V177I/M178V/K179Q/del.182R/F183S 0.86 1.43 0.60 1.67 1.05 0.30
G4(6) F183S 1.29 0.90 1.41 0.70 1.09 0.21
G4(7) Del. 182R/F183S 1.21 0.82 1.43 0.70 1.27 0.23
G5(1) G1(1)  G2(2) 1.15 0.53 2.19 0.45 1.26 0.46
G5(2) G1(1)  G2(4) 1.85 2.62 0.71 1.39 0.91 0.20
G5(3) G1(1)  G4(7) 1.51 0.90 1.67 0.61 1.44 0.30
G5(4) G2(1)  G4(7) 1.28 0.07 18.0 0.05 1.33 1.70
G5(5) G2(1)  G1(4) 1.29 0.06 21.7 0.05 1.31 1.82
G5(6) G1(1)  G4(7)  G2(5) 1.51 0.52 2.78 0.35 1.43 0.62
G5(7) G2(1)  G4(7)  G1(4) 1.66 0.08 20.4 0.05 1.45 1.80
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this group showed a highly significant improvement (0.36 
0.028) in EC50 relative to pGH WT.
To further improve pGH analogue biopotency, the biopo-
tency-improved variants in groups 1, 2, and 4 were combined
into group 5 (G5). As seen in Table I, most of the combination
mutants in G5 showed that higher biopotency was achieved by
the approach, except for G5 (2) where residues decreasing
biopotency (K63R/D64E) were included.
Themost significant improvement in biopotency was seen with
the combined analogues G5(3), G5(5), G5(6), and G5(7), which
had 4.6-, 4.1-, 4.5-, and 5.1-fold increases in biopotency, respec-
tively, compared with pGHWT (Table I and Fig. 2). The greatest
biopotency-improved analogue, G5(7), consisted of 10 mutations:
R41K/Inserted 44F/I45L/T61S/G62N/K63R/D64E/A66T/
del.182R/F183S. However, a mutant with only 5 residue changes
(G5(3)) possessed a biopotency very close to that of G5 (7).
For regulatory reasons, it was important to determine
whether these increased biopotency pGH mutants cross-react
with the hGH receptor. Analysis with the BAF/B03 cell line
expressing hGHR revealed that pGH wild type could not acti-
vate the hGHR up to 50 nM and this was the case for all pGH
analogues except for group 3 analogues and, to a minor extent,
for group 5 (7). This is illustrated in Fig. 3 and Table II, which
show that pGH mutant G3(1) L168M/H169D/A171V has a 19-
fold lower potency for hGH receptor than hGH itself, and mu-
tant G3(2) K165R/L168M/H169D/A171V reaches one-fifth the
potency of hGH. However, these mutants are 2–3-fold less
potent than pGH in the pGH receptor-based cell bioassay. To
understand the basis for the differences in biopotency observed
with these hybrid pGH mutants, we undertook biosensor anal-
ysis for binding kinetics with immobilized pGHR extracellular
domain (ECD or GHBP).
FIG. 4. Representative sensorgrams showing association and dissociation kinetics for pGH wild type and mutants binding with
pGHBP. The simulated sensorgrams from simultaneous and global fit of the experimental data are shown superimposed upon the experimental
sensorgrams. All sensorgrams were from pGHBP(S201C) on the SA Biosensor Chip after injections of serial dilutions of pGH wild type and pGH
mutants at 60, 30, 15, 7.5, 3.75, and 0.5 nM. A, injection of pGHmutants group 1-1 (G1(1)) and group 2-1 (G2(1)); B, injection of pGHmutants groups
3-1 (G3(1)) and 4-7 (G4(7)); C, injections of the combinations of affinity improved pGH mutants.
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Kinetic Parameters—Two GHR ECD orientations were used
for these studies, based on studies with the hGHR ECD (1). In
this case, immobilization through S201C prevents dimer for-
mation between ECDs, and yields site 1 kinetic parameters,
whereas immobilization through S237C allows hormone-in-
duced dimer formation, and provides an overall measure of
complex formation similar to binding to intact receptor at the
cell surface. This is verified for the pGHR ECD in Table III,
which shows that the maximum binding stoichiometry for pGH
binding to S201C immobilized ECD approached 1.0, whereas
the stoichiometry for S237C ECD was close to 0.5. It is notable
that the absolute values for off- and on-rate constants do not
differ markedly between pGH and hGH binding to their respec-
tive ECDs. The calculated KD values (Table III) are similar to
the values reported by the Genentech group (1), indicating that
the purified ECDs were correctly refolded and immobilized.
Binding parameters for site 1 using the S201C pGHR ECD
are presented in Table IV and representative sensorgrams in
Fig. 4. hGH is seen to have a marginally lower on-rate that WT
pGH. It can be seen that only the minihelix substitution R41K/
Insert44F/I45L significantly increases the on-rate constant,
and this is largely a result of substitution of Lys for Arg at
position 41. This substitution essentially doubled the affinity
constant. In support of this conclusion, combination mutants
with the minihelix substitution also show an increased on-rate,
except when decreased by another mutation.
Analysis of off-rates was more revealing (Table IV). The
off-rate for hGH binding to S201C pGHR ECD is 12.5 times
slower than for pGH, and this accounts for the 9-fold higher
affinity of hGH for the pGHR ECD. This decreased off-rate
appears to be a result of residues in the extended loop between
helices 1 and 2, because substitution of only these 5 hGH
residues into pGH produces a comparable decrease in off-rate
constant as seen with hGH itself. Interestingly, with the ex-
ception of A66T, none of the individual or paired substitutions
in this sequence was able to decrease the off-rate. Evidently the
entire 5-residue substitution is required, and this is confirmed
in the combination mutants. This difference in the off-rate is
sufficient to increase the affinity constant by over 20-fold, ex-
ceeding that of hGH itself.
Analysis of the 20 mutants with the S237C pGHR ECD chip
was also revealing (Table V). In all cases the on-rate constant
was greater than the corresponding S201C pGHR ECD value,
although the effect was less than 2-fold. The off-rate constants
with hGH and most of the pGHmutants are less than the value
with S201C pGHR EC, presumably as a result of the stabiliza-
tion associated with formation of the ternary complex. How-
ever, this is not the case for mutants involving the extended
loop between helices 1 and 2, either alone or in combination
with other mutations. Evidently the stabilization of site 1 bind-
ing that results from substitution of the 5 extended loop resi-
dues is sharply decreased on formation of the ternary complex.
Primate Specificity Determinants—The basis for increased
biopotency of Group 3 fourth helix substituents seen in the
hGH receptor-based cell bioassay was investigated using a
S201C hGHR ECD sensor chip. As shown in Table VI, the
on-rate constant was the critical factor in determining affinity.
Previously (15) we showed that His169 is the key primate spec-
ificity determinant, and this was verified here. In addition, the
K165R substitution was able to further increase the on-rate
constant by a factor of nearly 3-fold. This allowed the mutant
pGH to bind to hGH receptor site 1 with an affinity exceeding
one-tenth that of wild type hGH, similar to its one-fifth biopo-
tency in the cell assay.
Relationship between Kinetic Parameters and Biopotency—
As illustrated in Fig. 5, across the 20 pGH mutants there is a
linear relationship between normalized site 1 biopotency and
the normalized site 1 dissociation constant, obtained with the
S201C pGHR ECD chip. This linear relationship also applies
for the S237C pGHR ECD chip. This relationship is not seen
with hGH (10).
DISCUSSION
This study has shown that, in contrast to hGH (10), pGH is
not “evolutionarily optimized,” and can be mutated to improve
its biopotency. Indeed, there is a linear relationship between
site 1 affinity of pGH and biopotency over a 10-fold range. This
accords with the predictions of Illondo et al. (8) and Matthews
et al. (9) for hormone-induced dimerization of a cytokine recep-
tor. However, the finding that a 400-fold increase in site 1
affinity for hGH or a 40-fold increase in affinity for site 2, did
not result in any increased biopotency led Pearce et al. (10) to
examine these predictions more closely, and to propose that the
limiting factor in receptor activation was diffusion of the second
receptor to the hormone-receptor 1 complex. They argued that
because site 1 affinity needed to be reduced over 50-fold to see
TABLE V
Relative on-rates, off-rates, and affinities for pGH mutants and hGH to pGHbp(S237C) immobilized on the SA-matrix of BIAcore biosensor
The relative change in on-rate was calculated from Kon Mut/Kon WT and off-rate from Koff Mut/KoffWT. The change in KD was calculated as
[Koff /Kon (Mut)]/[Koff /Kon (WT)] and KA from 1/KD. The values of Rmax were calculated from Rmax Mut/Rmax WT.
Ligands Residues by mutagenesis
Changes in kinetics (Mut/WT)
On-rate Off-rate KA KD Rmax
PGH 1.00 1.00 1.00 1.00 1.00
HGH 0.80 0.05 16.0 0.06 1.11
G1(1) R41K/Ins.44F/I45L 1.28 0.69 1.81 0.55 1.16
G1(3) R41K 1.12 1.25 0.89 1.11 1.01
G1(4) Ins.44F/I45L 1.08 1.13 0.97 1.04 1.06
G2(1) T61S/G62N/K63R/D64E/A66T 1.10 0.27 4.18 0.24 1.18
G2(2) T61S/G62N 0.91 0.82 1.10 0.90 1.00
G2(4) K63R/D64E 0.89 1.24 0.75 1.34 0.85
G2(5) A66T 0.88 0.82 1.10 0.93 1.08
G4(3) V177I/M178V/K179Q/del.182R/F183S 0.90 1.00 0.90 1.08 1.02
G4(6) F183S 1.26 0.81 1.56 0.66 1.04
G4(7) Del.182R/F183S 1.26 0.78 1.56 0.62 1.17
G5(1) G1(1)  G2(2) 1.16 0.75 1.52 0.67 1.16
G5(2) G1(1)  G2(4) 1.45 1.94 0.73 1.37 1.02
G5(3) G1(1)  G4(7) 1.38 1.11 1.14 0.89 1.28
G5(4) G2(1)  G4(7) 1.21 0.77 1.56 0.61 1.11
G5(5) G2(1)  G1(4) 1.04 0.40 2.48 0.40 1.24
G5(6) G1(1)  G4(7)  G2(5) 1.54 1.25 1.25 0.75 1.27
G5(7) G2(1)  G4(7)  G1(4) 1.40 0.94 1.50 0.63 1.27
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a decrease in biopotency, the binding to site 1 far exceeds the
requirement to immobilize the hormone until the second recep-
tor formed the active ternary complex. A comprehensive set of
calculations accounting for membrane diffusion rates during
the receptor dimerization process showed that, based on the
dimerization model and a conservative estimate of cell diame-
ter and receptor density, no change in hormone biopotency was
possible unless the affinity was reduced at least 20-fold. How-
ever, our BIAcore analysis shows that site 1 affinity of pGH for
its receptor is only slightly less than that of hGH for its recep-
tor site, yet we find a linear relationship between site 1 affinity
and biopotency for pGH, so the diffusion limited argument does
not appear to apply.
An alternative explanation is that the phage display-ma-
tured hGH binds in a less signaling competent manner to its
receptor than the wild type hormone. It is clear from the crys-
tallography study of Schiffer et al. (16) that phage display
mutations alter the way that site 1 binds to its receptor, but
what was surprising in this study was that site 2 interactions
are also very different in the crystal structure, even though the
mutations were introduced exclusively in site 1. We find, con-
versely, that site 2 and dimerization domain interactions can
alter site 1 interactions, as exemplified by the decrease in
affinity with S237C pGHR ECD (which detects ternary com-
plex formation) when high affinity mutants involving the ex-
tended loop between helices 1 and 2 (site 1) are examined. In
this case alone, the affinity for the S237C pGHR ECD chip is
lower than the affinity for the S201C chip, implying that site 2
and inter-receptor interactions destabilize site 1 interactions.
This is presumably a result of disturbing the packing around
the key hydrophobic binding hotspot that involves the two
tryptophans, Trp104 and Trp169 (2). The loss of overall (S237C)
affinity we observe in this case may contribute to preventing a
further increase in biopotency beyond the 5-fold wild type, even
though the site 1 affinity increase is over 20-fold.
In the simple hormone-induced receptor dimerization model,
the manner in which the receptor subunits bind to the hormone
is of little relevance. However, we have recently proposed a new
model for GH receptor activation that is based on relative
rotation of subunits within a pre-existing receptor dimer.2 In
this model, relative orientation of receptor subunits is critical
for effective signaling, as has been shown for the homologous
erythropoietin receptor (17). We suggest that the reason that
the phage display variants of hGH were unable to improve
TABLE VI
Relative on-rates, off-rates, and affinities for pGH mutants binding to hGHBP and pGHBP immobilized on the SA-matrix of BIAcore biosensor
The relative change in on-rate was calculated from Kon Mut/Kon WT and off-rate from Koff Mut/ KoffWT. The change in KD was calculated as
[Koff /Kon (Mut)]/[Koff /Kon (WT)] and KA from 1/KD. The values of Rmax were calculated from Rmax Mut/Rmax WT. Absolute values for wt pGH and
hGH are given in parentheses: Values for mutants are relative to WT that are normalized to 1.0.
GHR Ligand Residues by mutagenesis
Changes in kinetics (Mut/WT)
On-rate Off-rate KA KD Rmax
1/ms 1/s 1/M M RU
1 1 1 1 1
HGH (1.95) (3.54) (5.58) (1.89) (43)
pGH NB NB NB NB NB
hGHBP(S201C) G3(1) L168M/H169D/A171V 0.08 2.41 0.03 29.6 0.24
G3(2) K165R/L168M/H169D/A171V 0.23 2.22 0.11 9.60 0.43
G2(1) T61S/G62N/K63R/D64E/A66T NBa NB NB NB NB
G2(2) T61S/G62N NB NB NB NB NB
G2(4) K63R/D64E NB NB NB NB NB
G2(5) A66T NB NB NB NB NB
1 1 1 1 1
pGH (1.85) (6.84) (2.78) (3.79) (38)
pGHBP(S201C) G3(1) L168M/H169D/A171V 1.06 1.62 0.63 1.57 0.63
G3(2) K165R/L168M/H169D/A171V 1.31 1.09 1.18 0.85 1.06
1 1 1 1 1
pGH (2.35) (2.54) (9.28) (1.19) (42)
pGHBP(S237C) G3(1) L168M/H169D/A171V 1.48 1.28 1.15 0.86 0.72
G3(2) K165R/L168M/H169D/A171V 1.52 1.04 1.46 0.67 0.92
a NB, no binding.
FIG. 5. Relationship between biopotency and kinetics of por-
cine GH analogues. A shows EC50 mutant/EC50 wild type versus the
KD mutant/KD wild type with pGHBP(S201C). B shows binding with
pGHBP(S237C) on sensor chip SA. The values for Biopotency and
kinetics are shown in Tables I and III, respectively, except for the data
from group 3. Correlation with Koff was weaker, for both S201C GHBP
(r2  0.44) and S237C GHBP (r2  0.21).
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biopotency is that they caused misalignment of receptor sub-
units in some way, which resulted in a lower proportion of
occupied receptors initiating their response at a given hormone
concentration. In this view, the pGH mutants identified here
were able to act more efficiently, because they preserve the
framework needed for signaling-competent alignment of recep-
tor subunits, which is present in hGH.
We have undertaken homology modeling and molecular dy-
namics studies to understand the bases for the changes in site
1 kinetics that we observe with our mutants. Our homology
model for the pGH receptor, based on the human structures,
shows that the substitutions influencing on-rate (R41K/
Insert44F/I45L) in the minihelix between helices 1 and 2 can be
explained by two effects. The first is an improvement in the
minihelix structure and stability as a result of insertion of
the Phe, evident in molecular dynamics simulations that
show greater mobility of the wild type minihelix. The second
contributing factor appears to be the ability of human Lys41
to form a productive salt bridge with Glu127 of the receptor,
where Arg41 of pGH forms only a hydrogen bond to receptor
Cys122.
The reduction in off-rate associated with the group of 5
substitutions in the extended loop between helices 1 and 2
(T61S/G62N/K63R/D64E/A66T) most likely relates to their role
in packing around the important tryptophans Trp104 (hGH
Ser62) and Trp169 (hGH Arg64), which are known to determine
the off-rate (1). There are also additional bonds that are pre-
dicted to be present with the introduced human sequence that
are absent with WT pGH (see Fig. 6). Thus, human Arg64 forms
an ionic bond with receptor Asp164, and an ionic bond with
Glu44, whereas porcine Lys63 is able to form only an ionic bond
to Asp164. Arg64 packs closely with receptor Trp169, so its posi-
tioning is important. In addition, the carbonyl of hGH Ser62
forms a hydrogen bond to the amide of receptor Ile103, which is
important in positioning receptor Trp104. Another important
factor is likely to be the ability of carbonyl of the side chain of
Asn63 of hGH (Gly in pGH) to form a hydrogen bond with the
backbone amide of hGH Glu66, which acts to stabilize the loop
(referred to as an ASX motif (18)). Moreover, the backbone
carbonyl of Asn63 hydrogen bonds to the hydroxyl side chain of
Thr67 (Ala in pGH). These stabilizing hydrogen bonds are likely
to influence the positioning of human Arg64, which forms im-
portant contacts with receptor Trp169.
An analysis of sequences from different species, together
with the original alanine scanning study of Cunningham et al.
(19) and the crystal structure of the 2:1 complex, led Sousa et
al. (20) to show that Asp171 of hGH (His in non-primate GH) is
the primary determinant responsible for the inability of non-
primate GH to activate the human receptor. We subsequently
analyzed this in detail, with both receptor and hormone sub-
stitutions and modeling studies, showing the incompatibility of
His169 of pGH opposite the primate receptor Arg43 (15). Here
we independently confirm our earlier conclusions about Asp171-
His169, and also find that a further substitution of primate Arg
(i.e. Arg167 of hGH) at Lys165 results in a pGH mutant that is
able to activate the human receptor with only 5-fold lower
FIG. 6. A, hGH/hGH receptor crystal structure (Protein Data Bank codes 1HWG and 3HHR) showing extended loop residues (Group 2) of hGH,
their packing with the key two tryptophans of receptor 1, and their hydrogen bonds/ionic interactions with the receptor. Also shown as a white
ribbon is the ASX motif positioned by two hydrogen bonds, which confers rigidity to this loop and stabilizes interactions around the hydrophobic
core. Distances are shown in angstroms. B, comparison of the ASX motif in the hGH extended loop with conformation of homologous pGH loop
residues, derived from the homology model. Note the absence of two key hydrogen bonds in pGH prevents formation of the stabilized ASX motif.
C, key residues conferring primate species specificity in the hGH/hGHR crystal structure, and D, comparison with equivalent residues in the pGH
homology model.
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potency than hGH itself. This is confirmed with kinetic analy-
sis, which shows that the Arg substitution at Lys165 increases
the on-rate a further 4-fold. As shown in Fig. 6, this appears to
be a result of altered interactions with key electrostatic con-
tributors to binding in the linker region between cytokine ho-
mology modules (Asp126 and Glu127). It can be seen in the N-1
and N-2 of Arg167 in the hGH hydrogen bond/salt bridge to the
O-1 of Glu127 hGHR (5). This Arg is also sufficiently close to
the carboxy1 group of Glu126 to form a productive salt bridge
(4.3 Å). In the case of pGH, Lys165 also hydrogen bonds to
Glu127, but cannot form the additional salt bridge to Glu126.
This appears to be the only additional bond that can be formed
with hGH, and its absence could explain the 3-fold loss of site
1 affinity and 4-fold loss in biopotency seen against the hGHR.
However, this loss of affinity is not seen in the homologous
pGH-pGHR interaction, because the longer Glu126 side chain of
pGH allows electrostatic interaction with Lys165 of pGH, and
His169 could also form a weak ionic interaction with Glu126.
Our report of the creation of higher potency cytokine ana-
logues is not unique, although we have been unable to find any
literature reports of protein engineering that has resulted in
significantly higher potency class 1 cytokine analogues. Okabe
et al. (21) reported that the in vitro potency granulocyte colony-
stimulating factor could be increased up to 4-fold by 5 substi-
tutions identified from a screen of about 100 mutations. Gen-
erally, cytokine potency has otherwise been increased in vivo
by PEGylation (e.g. tumor necrosis factor- (22)), altered gly-
cosylation (e.g. granulocyte colony-stimulating factor (23) and
erythropoietin (24)), removal of residues responsible for bind-
ing to a competing binding protein (e.g. insulin-like growth
factor-1 (25)), or by making a fusion protein with another
bioactive protein (interleukin-3 (11)). In these cases the in-
creased biopotency results mainly from prolonged half-life.
In conclusion, in contrast to human GH, it has been possible
to engineer higher potency analogues of porcine GH by increas-
ing site 1 affinity, and this may apply for other non-primate
hormones. The finding that there is an essentially linear rela-
tionship between site 1 affinity and biopotency has important
implications for understanding the process of growth hormone
receptor activation.
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